论文部分内容阅读
目的探讨晚期非小细胞肺癌行化疗时中医药联合治疗方式的临床价值。方法选取2008年~2011年收治的晚期非小细胞肺癌患者30例,随机分为两组,分别行GP化疗与联合参麦注射液中药治疗。结果治疗组患者治疗总有效率相比对照组无显著差异,疾病控制率相比对照组显著提高,治疗组患者治疗后生活质量相比治疗前与对照组治疗后均显著提高,不良反应发生率显著低于对照组。结论参麦注射液中药联合化疗治疗晚期非小细胞肺癌能够有效提高癌症控制效果,改善患者生活质量,降低化疗不良反应,具有较高的临床价值。
Objective To investigate the clinical value of combination therapy of traditional Chinese medicine (TCM) in the treatment of advanced non-small cell lung cancer. Methods Thirty patients with advanced non-small cell lung cancer admitted from 2008 to 2011 were randomly divided into two groups, treated with GP chemotherapy and combined with Shenmai injection. Results The total effective rate of treatment group was no significant difference compared with the control group, disease control rate was significantly higher than the control group, the quality of life after treatment in treatment group compared with before treatment and control group after treatment were significantly increased, the incidence of adverse reactions Significantly lower than the control group. Conclusion Shenmai injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer can effectively improve the cancer control effect, improve the quality of life of patients and reduce adverse reactions of chemotherapy, which has high clinical value.